oxytocin orifarm 5 ie
orifarm generics a/s - oksytocin - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 5 ie
oxytocin orifarm 10 ie
orifarm generics a/s - oksytocin - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 10 ie
syntocinon 6.7 mikrog/ dose
alfasigma s.p.a - oksytocin - nesespray, oppløsning - 6.7 mikrog/ dose
vetocin 10 ie/ ml
bela-pharm gmbh & co. kg - oksytocin - injeksjonsvæske, oppløsning - 10 ie/ ml
oxytocin aurora medical 5 ie
2care4 aps - oksytocin - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 5 ie
oxytocin aurora medical 5 ie
2care4 aps - oksytocin - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 5 ie
syntocinon 6.7 mikrog/ dose
orifarm as - oksytocin - nesespray, oppløsning - 6.7 mikrog/ dose
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
pabal 100 mikrog/ ml
ferring legemidler as - karbetocin - injeksjonsvæske, oppløsning - 100 mikrog/ ml